Sorenson John Bradley

SEC source: 0001225208-25-004792 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,705

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-004792 · doc4.xml · derivative · entry 4

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,204

Underlying: Common Stock · 4,204 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-25-004792 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,277

SEC source: 0001225208-25-004792 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,195

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-001971 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,991

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $105.02 to $105.365, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-001971 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,294

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 12

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,500 shares

Expires 2025-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 7

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,951

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 6

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,635

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 11

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,273

Underlying: Common Stock · 1,273 shares

Expires 2026-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F6 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

F6 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 5

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,135

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 4

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 10

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,230

Underlying: Common Stock · 2,115 shares

Expires 2027-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,443

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,644

SEC source: 0001225208-25-001878 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 27,609

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 9

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,909

Underlying: Common Stock · 10,909 shares

Expires 2035-02-13

F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

SEC source: 0001225208-25-001878 · doc4.xml · derivative · entry 8

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,239

Underlying: Common Stock · 4,239 shares

Expires 2029-02-13

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.

SEC source: 0001225208-25-001686 · doc4.xml · nonDerivative · entry 4

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,293

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.81 to $105.26, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-001686 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,682

SEC source: 0001225208-25-001795 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,193

Underlying: Common Stock · 1,731 shares

Expires 2028-02-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

SEC source: 0001225208-25-001795 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,494

SEC source: 0001225208-25-001795 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-25-001686 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,838

SEC source: 0001225208-25-001686 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,631

F1 · kind: On February 16, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2024 and subject to the completion of the concurrent three-year individual service period. On February 11, 2025, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.

SEC source: 0001225208-25-001451 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,449

F1 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-000208 · doc4.xml · nonDerivative · entry 4

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,977

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $89.524 to $90.15, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-25-000208 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,319

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-25-000208 · doc4.xml · derivative · entry 5

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,469 shares

Expires 2024-12-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.exercise_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

F1 · derivative.expiration_date: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-25-000208 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,438

SEC source: 0001225208-25-000208 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,565

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On February 10, 2022, the reporting person was awarded a target number of performance share units under the Company's 2022 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2022 adjusted free cash flow measured against its 2022 financial plan over the one-year performance period ending December 31, 2022 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 14, 2023, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2024.

SEC source: 0001225208-24-009902 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,096

SEC source: 0001225208-24-009878 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,362 shares

Expires 2027-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.

SEC source: 0001225208-24-009878 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,706

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $87.324 to $87.94, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-009878 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.

SEC source: 0001225208-24-005660 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,408

Underlying: Common Stock · 4,203 shares

Expires 2026-05-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.

SEC source: 0001225208-24-005660 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,924

SEC source: 0001225208-24-005660 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,841

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

SEC source: 0001225208-24-005479 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,587 shares

Expires 2026-02-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.

SEC source: 0001225208-24-005479 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,638

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $71.201 to $71.83, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-005479 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.

SEC source: 0001225208-24-004849 · doc4.xml · derivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,351 shares

Expires 2025-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.

F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant.

SEC source: 0001225208-24-004849 · doc4.xml · nonDerivative · entry 2

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,638

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $68.10 to 68.53, inclusive. The reporting person undertakes to provide upon request bythe U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001225208-24-004849 · doc4.xml · nonDerivative · entry 1

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,989

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 6, 2023.

SEC source: 0001225208-24-002579 · doc4.xml · derivative · entry 9

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,186 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.

F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 18, 2021, the first anniversary of the date of grant.

SEC source: 0001225208-24-002579 · doc4.xml · nonDerivative · entry 6

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,638

SEC source: 0001225208-24-002579 · doc4.xml · nonDerivative · entry 5

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,179

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each deferred stock unit represents the Company's commitment to issue on share of Boston Scientific common stock.

SEC source: 0001225208-24-002579 · doc4.xml · derivative · entry 8

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,500

Underlying: Common Stock · 1,500 shares

Expires 2025-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant.

SEC source: 0001225208-24-002579 · doc4.xml · nonDerivative · entry 4

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,993

SEC source: 0001225208-24-002579 · doc4.xml · nonDerivative · entry 3

Sorenson John Bradley · CIK 0001629277 · EVP, Global Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,678

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.